[1]Patent:US2008/90856,2008,A1,.Locationinpatent:Page/Pagecolumn49
[2]Patent:WO2013/36232,2013,A2,.Locationinpatent:Paragraph00358
[1]Patent:WO2013/36232,2013,A2,
[1]Patent:WO2013/36232,2013,A2,
[1]Patent:WO2013/36232,2013,A2,
[1]Patent:WO2013/36232,2013,A2,
[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2008/90856,2008,A1Locationinpatent:Page/Pagecolumn49
[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2Locationinpatent:Paragraph00358
[3]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1Locationinpatent:Paragraph0474
[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2008/90856,2008,A1Locationinpatent:Page/Pagecolumn49
[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2Locationinpatent:Paragraph00358
[3]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1Locationinpatent:Paragraph0474
[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2
[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1
[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2
[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1
[1]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-WO2013/36232,2013,A2
[2]CurrentPatentAssignee:DECIPHERAPHARMACEUTICALSLLC-US2021/275518,2021,A1
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Journal: Current oncology reports 20121001
Title: The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Journal: Blood 20111110
Title: The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Journal: Cancer research 20110501
Title: Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Journal: Cancer cell 20110412
Title: Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110115
Title: Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011, 19(4), 556-568.